N-(pyridin-3-ylmethyl)pivalamide | 109902-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(pyridin-3-ylmethyl)pivalamide
• 英文别名: 2,2-dimethyl-N-(3-pyridylmethyl)propanamide；2,2-dimethyl-N-(pyridin-3-ylmethyl)propanamide
• CAS: 109902-24-1
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD00495414
• 分子量: 192.261
• InChiKey: DCVZJZBQSGOVEP-UHFFFAOYSA-N

物化性质

• 沸点：
  381.6±25.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(pyridin-3-ylmethyl)pivalamide 、 碘乙烷 在 叔丁基锂 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 4.0h， 以90%的产率得到N-[(4-ethylpyridin-3-yl)methyl]pivalamide
  参考文献：
  名称：

  Control of Site of Lithiation of 3-(Aminomethyl)pyridine Derivatives

  摘要：

  Lithiation of N-(pyridin-3-ylmethyl)pivalamide, tert-butyl N-(pyridin-3-ylmethyl)carbamate, and N,N-dimethyl-N-(pyridin-3-ylmethyl)urea with tert-butyllithium (3 equiv) in anhydrous tetrahydrofuran at -78 degrees C takes place on the nitrogen and on the ring at the 4-position. The dilithium reagents thus obtained react with various electrophiles to give the corresponding substituted derivatives in high yields. On the other hand, regioselective side-chain lithiation occurs with lithium diisopropylamide (3.3 equiv) at -20 to 0 degrees C. A mixture of ring and side-chain substitution products is obtained with n-butyllithium as the lithium reagent. Treatment of one of the ring-substituted products with trifluoroacetic anhydride in dichloromethane under reflux conditions led to formation of the corresponding 1H-pyrrolo[3,4-c]pyridine in high yield.

  DOI：

  10.1055/s-0033-1338547
• 作为产物：
  描述：

  3-氨甲基吡啶 、 三甲基乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以94%的产率得到N-(pyridin-3-ylmethyl)pivalamide
  参考文献：
  名称：

  Control of Site of Lithiation of 3-(Aminomethyl)pyridine Derivatives

  摘要：

  Lithiation of N-(pyridin-3-ylmethyl)pivalamide, tert-butyl N-(pyridin-3-ylmethyl)carbamate, and N,N-dimethyl-N-(pyridin-3-ylmethyl)urea with tert-butyllithium (3 equiv) in anhydrous tetrahydrofuran at -78 degrees C takes place on the nitrogen and on the ring at the 4-position. The dilithium reagents thus obtained react with various electrophiles to give the corresponding substituted derivatives in high yields. On the other hand, regioselective side-chain lithiation occurs with lithium diisopropylamide (3.3 equiv) at -20 to 0 degrees C. A mixture of ring and side-chain substitution products is obtained with n-butyllithium as the lithium reagent. Treatment of one of the ring-substituted products with trifluoroacetic anhydride in dichloromethane under reflux conditions led to formation of the corresponding 1H-pyrrolo[3,4-c]pyridine in high yield.

  DOI：

  10.1055/s-0033-1338547

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• ARBOVIRUS INHIBITORS AND USES THEREOF
  申请人：Larsen Scott

  公开号：US20120252807A1

  公开（公告）日：2012-10-04

  The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of arboviruses.

  本发明涉及化学化合物、其发现方法以及其治疗用途。具体而言，本发明提供了作为虫媒病毒抑制剂的化合物。
• RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Buckmelter Alexandre J.

  公开号：US20100063066A1

  公开（公告）日：2010-03-11

  Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物(I)、(IIA)和(IIIA)的配方对抑制Raf激酶和治疗由此介导的疾病很有用。公开了使用化合物(I)、(IIA)和(IIIA)及其立体异构体和药用盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病或相关病理状况的方法。
• HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
  申请人：Miyaji Katsuaki

  公开号：US20090253751A1

  公开（公告）日：2009-10-08

  Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 , R 2 , R 3 , L 1 , L 2 , X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了一种用于预防、治疗或改善激活血小板生成素受体有效对抗的疾病的化合物。该化合物由式(I)所表示（其中R1、R2、R3、L1、L2、X和Y在描述中被定义），该化合物的互变异构体、前药或药物可接受的盐或其溶剂化物。
• DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Chu Lin

  公开号：US20100152185A1

  公开（公告）日：2010-06-17

  The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  本发明提供了式I的化合物，其是5-脂氧合酶激活蛋白的抑制剂。式I的化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。